Tvp-1012
Synucleinopathies
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Synucleinopathies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Donanemab Eli Lilly and Company | Phase 2 | CCC |
RDX-013 COMPONENT TENAPANOR Cedar Valley Digestive Health Center | Phase 2 | CCC |
PBR-06 Brigham and Women's Hospital | D | |
[18F]MNI-1216 Invicro | Early Phase 1 | NR |
Same molecule, other indications
Tvp-1012 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →